|Short Name||Acronym Origin||Title||Study Description||Start Date||Status|
|ACUMIN||Acute Care Unit Tetracycline antibiotic||A Phase IV, Open-Label Pharmacokinetic Study of Tetracycline Antibiotic for Injection Following a Single Infusion in Critically-Ill Adults||PK/PD of a single infusion of an intravenous tetracycline antibiotic among critically ill adults||2/4/2016||Database Lock|
|ADAPT||ADAPTive Design||Platform Trial for the Evaluation of Antimicrobials for the Treatment of Multiple Resistant Bacterial Pathogens in Bacteremia||An innovative initiative to design and simulate a clinical platform trial that is customized to efficiently evaluate multiple experimental antimicrobial therapies for the treatment of multiple categories of infections (HAP/VAP, UTI and IA) due to MDR bacterial pathogens. The team consists of statisticians and clinicians from Berry Consultants, ARLG, GSK, Roche, AstraZeneca, The Medicines Company, JHU, BARDA, Sanofi, and the FDA.||9/10/2015||Completed|
|BCID||Film Array Blood Culture ID Panel||Clinical and Economic Impact of Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles||A prospective, randomized controlled trial with the primary objective being to determine if the BCID test either alone, or in combination with antimicrobial stewardship, will impact the antimicrobial utilization, clinical outcomes, and healthcare costs of patients with bloodstream infections.||12/17/2013||Published|
|CEF_BP||Ceftriaxone Breakpoint||Development of a Multicenter Gram-negative Database to Establish Clinically Relevant Antibiotic Breakpoint Interpretative Criteria for Ceftriaxone||A retrospective, observational propensity score-matched study of patients 18 years or older with monomicrobial Gram-negative bacteremia with the primary objective being:
to compare clinical outcomes of adult patients with Gram-negative bacteremia with organisms with minimum inhibitory concentrations between 4-8 µg/ml who received ceftriaxone compared with broader-spectrum antibiotic agents
|CEPCON||Pharma Company Controls||Collection of Rectal and Oropharyngeal Swabs from Healthy Volunteers||Collection of rectal and oropharyngeal swabs from healthy controls for the development of an assay||6/11/2015||Enrollment Complete
Samples used for Platform Validation
|COMBINE||AVYCAZ® in COMBINation with Aztreonam
|A Phase I, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ® in Combination with Aztreonam||A single center study in healthy adult subjects to investigate the safety and pharmacokinetics of ceftazidime-avibactam (AVYCAZ) combined with aztreonam (ATM), AVYCAZ alone, and ATM alone.||12/6/2017||Enrolling|
|CRACKLE||Consortium on Resistance against Carbapenems in Klebsiella pneumonia||Consortium on Resistance against Carbapenems in Klebsiella Pneumoniae and other Enterobacteriaceae||An observational study that utilizes an existing CRKP consortium consisting of 20 hospitals that are part of 9 different health care systems. The primary objectives were:
1) To determine whether CRKP strain type is associated with outcomes in CRKP infections 2) To evaluate the constellation of clinical and microbiologic factors associated colistin and tigecycline non-suspectibility
3) To explore variation in treatment and outcomes of CRKP infections in various anatomical sites.
|CRACKLE II||Consortium on Resistance against Carbapenems in Klebsiella pneumonia and other Enterobacteriaceae||Consortium on Resistance against Carbapenems in Klebsiella pneumoniae and other Enterobacteriaceae: A Prospective, Observational Cohort Study||A prospective, multicenter, observational cohort study with the objective of providing observational data that will aid in the design of randomized clinical trials on therapeutics and diagnostics for CRE infections. The objectives are:
1) To identify target population and high volume centers
2) Provide data on impact of potential inclusion/exclusion criteria on enrollment in future trials
3) Provide data on expected outcomes of patients with CRE infections for power and sample size calculations for future trials
|CREST||Using Novel Molecular Beacons to study the impact of Carbapenem Resistant Enterobacteriaceae Carriage on the Outcomes of Solid Organ Transplant||Using Novel Molecular Beacons to Study the Impact of Carbapenem Resistant Enterobacteriaceae Carriage on the Outcome of Solid Organ Transplant||A prospective, observational study to evaluate the natural history of CRE carriage in intestine, liver, lung, pancreas, kidney, and heart transplant donors and recipients from time of transplant through 3 months post-transplant. The primary objectives are:
1) To determine CRE carriage rates among intestine, liver, lung, lung, pancreas, kidney, and heart transplant donors and recipients at time of transplant, and among recipients post-transplant
2) To follow transplant recipients for 3 months post-transplant for the development of CRE infections of colonization
3) To determine associations between CRE colonization, CRE infections, and outcomes like length of hospital stay, and rates of mortality, rejection, and allograft failure
4) To compare sensitivity and turn-around time of molecular beacon and culture-based CRE screening methods, using per-rectal, duodenal, colon, and lung swabs or bronchoalveolar lavage fluid
|CRKP-LTACH||The epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in long-term acute care hospitals (LTACH)||The Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in long-term Acute Care Hospitals||A clinical epidemiologic and microbiologic building on an existing collaboration that will focus on characterization of CRKP isolates from a network of LTACHs, including linkage to clinical epidemiologic characteristics. The primary objectives are:
1) To evaluate risk factors for relatedness of CRKP isolates from LTACH residents
2) To assess the impact of various resistance mechanisms, virulence factors, and capsular gene types on clinical outcomes in the LTACH setting
|8/12/2014||Manuscript in progress|
|DICON I||Refers to the Duke Infection CONtrol Network which provides access to the community hospitals doing research||A Multi-Center, Three-Stage Cluster-Randomized Historically Controlled Crossover Trial to Determine the Feasibility and Outcomes from Two Antimicrobial Stewardship Interventions in Community Hospitals||A multicenter, three-stage cluster-randomized historically controlled crossover trial with the primary objectives being:
1) To evaluate having the protocol of two stewardship intervention strategies approved by hospital administration and committees2) To evaluate the training of local PharmDs in administration of the two stewardship strategies3) To evaluate the initiation and implementation of the two stewardship strategies at four hospitals.
|DISK||Refers to the disk diffusion test method evaluated in the study||Rapid Disk Diffusion Test Direct from Patient Blood Cultures for the Detection of Antimicrobial Susceptibility of Gram Negative Rods||A multicenter study to evaluate the performance of disk diffusion performed using positive blood culture broth (BCB) as the inoculum. Because this test uses general purpose reagents, it can be performed in all laboratories including those without the expertise and resources for expensive and complex molecular testing.||8/10/2015||Analysis in Progress|
|DOTS||Randomized, Open-Label, Superiority Trial of a Lipopeptide antibiotic with Oral Oxazolidinone-class antibiotic Stepdown versus Standard Intravenous Therapy for Staphylococcus aureus Bacteremia||Randomized, Open-Label, Superiority Trial of Lipopeptide Antibiotic with Oral Oxazolidinone-class antibiotic Stepdown versus Standard Intravenous Therapy for Staphylococcus aureus Bacteremia||A multi-center, randomized, open-label study comparing two treatment strategies:
1) Initial lipopeptide antibiotic therapy (8 mg/kg IV q24h) for 14 days (or an anti-staphylococcal beta-lactam for those with MSSA), followed by oral Oxazolidinone-class antibiotic (200mg po 24h) for 21 additional days
2) Standard of Care, consisting of a Lipopeptide antibiotic (8mg/kg) for 14-42 days for subjects with MRSA, or an antistaphylococcal beta-lactam for subjects with MSSA
|FOCUS||The Fosfomycin Oral for Complicated Urinary Syndromes Study||A Phase IV Randomized, Double-blinded Trial to Evaluate the Efficacy of Oral Fosfomycin versus Levofloxacin in Complicated Urinary Tract Infections (cUTI)||A multi-center, randomized, double-blind, double-dummy, phase IV clinical trial of fosfomycin oral for complicated urinary syndromes.
Main objective: To compare the safety and efficacy of oral fosfomycin to levofloxacin for the treatment of cUTI including pyelonephritis
|FOCUS-PK||PAD FOCUS (Pharmacokinetics And Dynamics for FOCUS)||Pharmacokinetic Substudy of the Fosfomycin Oral for Complicated Urinary Syndromes (FOCUS) Trial||A substudy of the fosfomycin for complicated urinary syndromes (FOCUS), phase IV, multi-center, randomized, double-blind, double-dummy clinical trial comparing the efficacy of oral fosfomycin versus oral levofloxacin as therapy for complicated urinary tract infections. An intensive pharmacokinetic study performed in 40 randomized patients to develop the pharmacokinetic model, which will be used to identify patient covariates that contribute to altered PK. A randomized, placebo-controlled, active control study of oral fosfomycin as a step-down therapy for cUTI.||2/1/2015||Analysis in Progress|
|MASTER GC||Master Protocol - Gonorrhoeae and Chlamydia testing of extragenital specimens (pNAAT)||Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia trachomatis in Extragenital Sites||A cross-sectional study to evaluate the diagnostic accuracy of multiple commercially available nucleic acid amplification tests (NAATs) for detection of Neisseria gonorrhoeae and Chlamydia trachomatis from oropharyngeal and rectal sites.
The main objective: To estimate the sensitivities, specificities, positive predictive values, and negative predictive values for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in rectal and oropharyngeal swabs for each NAAT.
|12/2/2014||Platforms FDA Approved
|MicroFIRE||Microbiota Colonization in the Presence of Intestinal Fluoroquinolone Resistant E. coli||Microbiota Colonization in the Presence of Intestinal Fluoroquinolone Resistant (FQR) E. coli||Men, presenting for transrectal ultrasound guided prostate biopsy at hospital sites, who are colonized with FQR organisms have abnormal fecal microbiome diversity. Developing tests to analyze this microbiome can inform necessary precautions prior to future medical procedures. The goal is to analyze bacterial strains and their resistance profiles to allow development of rapid PR tests; investigate a rapid PCR test to detect various clonal groups, identify other clonal groups for testing.||4/14/2016||Manuscript in Progress|
|POP-MDRO||Prospective Observational Pseudomonas study - Multi-Drug ResistantOrganism Network||Prospective Observational Pseudomonas study as part of the Master protocol for prospective, multi-center, observational cohort studies||An international, multi-center study using the master protocol for prospective, multicenter, observational cohort studies to provide detailed clinical and microbiologic data in carbapenem-resistant P. aeruginosa (CRPA) pulmonary and bloodstream infections in hospitalized patients to inform future interventional and diagnostic studies.||8/31/2018||Completed|
|PRIMERS I-IV||Platforms for Rapid Identification of MDR-GNB, and Evaluation of Resistance Studies I-IV||Rapid Gene Detection of MDR GNB to Direct and Improve Patient Outcomes||A series of diagnostics studies with the goal of identifying efficient, cost-effective platforms with which to discriminate resistant and susceptible antibiotics by identifying and genotyping the bla genes of multi-drug resistant gram-negative bacterial isolates||6/1/2013||PRIMERS I and II
|PROOF||Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Three Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants||Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Three Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants||A randomized, three-way crossover trial involving up to 24 randomized participants, stratified by gender using permuted blocks, with an anticipated 25% drop-out rate to give a total of 18 evaluable healthy adult participants. The primary study objectives are:
1) To assess the safety and tolerability of three different oral dosage regimens of fosfomycin tromethamine in healthy adult participants
2) To estimate the fosfomycin pharmacokinetic parameters maximum plasma concentration and area-under-the-plasma concentration time-curve at steady-state in three different oral dosage regimens of fosfomycin tromethamine in healthy adult participants
|PROVIDE||Prospective Observational Study to Validate the Pharmacodynamic InDex for Vancomycin among Patients with MRSA Bloodstream Infections||Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections||A prospective, multi-center, observational study with the primary objectives:
1) To estimate the difference in failure rates among adult hospitalized patients with MRSA bloodstream infections, who have vancomycin AUDAY2/MICBMD ratios above 650 relative to those with AUCDAY2/MICBMD ratios less than 650
2) To estimate the difference in failure rates among adult hospitalized patients with MRSA bloodstream infections, who have AUCDAY2/MICETEST ratios less than 320
|RADICAL||Rapid Diagnostics in Categorizing Acute Lung Infections||A Host-Based mRNA Classifier for Differentiating Viral and Bacterial Etiologies of Acute Respiratory Tract Infection||An umbrella protocol plan to develop and evaluate a host-based assay to distinguish between bacterial, viral and non-infectious diseases, which could help reduce inappropriate antimicrobial use. The aims are: 1) To transfer the bacterial signature to an RT-PCR platform
2) To validate and optimize the ARI classifier using the TLDA technology; define performance characteristics compared to existing diagnostic standards
3) To work with bioFire Diagnostic Systems to develop a platform to improve turn-around time and feasibility time
4) To establish a regulatory pathway for commercialization opportunities
5) Early-phase Economic Modeling
|RADICAL II||Rapid Diagnostic in Categorizing Acute Lung Infections||Evaluation of a Rapid Diagnostic Test for the Categorization of Acute Respiratory Illness||A cross sectional, single visit study, in adults and children, to evaluate the diagnostic accuracy of a host response test to categorize the etiology of illness in patients presenting with acute respiratory symptoms, as compared to a clinical adjudication reference standard.
1) Compare the Host Response-Acute Respiratory Illness (HR-ARI) test to a clinically adjudicated reference standard with respect to bacterial, viral, or non-bacterial/non-viral (NB/NV) etiologies.
2) Evaluate performance of the HR-ARI test across age groups; 22-64 years; 65 or older), racial and ethnic distributions, and different enrollment sites.
3) Evaluate performance of the HF-ARI test in clinical subgroups such as COPD, immunosuppressed, and those with atypical bacterial pathogens (Legionella pneumophila, Mycoplasma pneumonia, and Chlamydophila pneumonia).
|RAPIDS-GN||Rapid Identification and Susceptibility Testing for Gram-Negative Bacteremia||Rapid Identification and Susceptibility Testing for Gram Negative Bacteremia||Multi-center, prospective, randomized, controlled trial to evaluate standard culture and antimicrobial susceptibility testing (AST) versus rapid identification and AST for patients with confirmed Gram-negative bacteremia.
The main study objectives are to evaluate the impact of rapid identification and AST on 1) the time to first antibiotic modification in the first 72 hours after randomization, 2) antimicrobial utilization, and 3) clinical outcomes.
|7/9/2015||Analysis in Progress|
|SCOUT-CAP||SCOUT (Previous Study) - Community Acquired Pneumonia||A Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia||A multi-center, centrally randomized, double-blind, placebo-controlled superiority clinical trial with the primary aim of comparing the composite overall outcome (Desirability of Outcome Ranking, DOOR) among children from 6 months to 5 years of age with CAP, assigned to a strategy of short course (5 days) vs. standard course (10 days) outpatient beta-lactam therapy.||5/7/2014||Enrollment Complete|
|SNAP-MDRO||Study Network of Acinetobacter baumannii as Carbapenem-Resistant Pathogen-Multi-Drug Resistant Organism Network||Study Network of Acinetobacter baumannii as Carbapenem-Resistant Pathogen as part of the Multi-Drug Resistant Organism Network||An international, multi-center study using the master protocol for prospective, multicenter, observational cohort studies to provide observational data from hospitalized patients that will aid in the design of randomized clinical trials on therapeutics and diagnostics for Carbapenem-Resistant Acinetobacter baumannii (CRAb) infections, as well as identify centers in geographic regions with the highest incidence of infection for future trial site selection.||8/31/2018||Enrollment Complete|
|SPICES||Study of Persistence of Intestinal Colonization with E. coli ST131||Study of Persistence of Intestinal Colonization with E coli ST131||A single-center, prospective, observational study to assess the duration of colonization with the problemative ST131 E. coli strain and identify risk factors for persistence in colonized patients and their household contracts (including pets). Colonization duration is being compared between FQ-R ST131 E. coli, FQ-S ST131 E. coli, and FQ-R E. coli of other sequence types. The study objectives are:
1) Define the duration of gut colonization with FQ-R ST131 strains in individuals and households
2) To identify host and household level risk factors for persistent colonization with FQ-R ST131
|STAR||Short-course Therapy and the Antibiotic Resistome||A Sub-Study to Evaluate Alterations in the Antibiotic Resistome and Microbiome in Subjects Who Received Short Course vs. Standard Course Therapy for Community-Acquired Pneumonia as part of DMID protocol #14-0079||SCOUT-CAP sub-study to look at the microbiome of stool and throat swabs in children with different duration of antibiotic therapy for treatment of CAP.||1/7/2015||Enrollment Complete|
|TRAP-LRTI||Targeted Reduction of Antibiotics using Procalcitonin in a multi-center, randomized, blinded, placebo-controlled, non-inferiority study of azithromycin treatment in outpatient adults with suspect Lower Respiratory Tract Infections (LRTI) and a procalcitonin level of < 0.1 ng/mL||Targeted Reduction of Antibiotics using Procalcitonin in a multi-center, randomized, blinded, placebo-controlled non-inferiority study of azithromycin treatment in outpatient adults with suspect lower respiratory tract infection (LRTI) and a procalcitonin level of < 0.1 ng/mL||The goal of this study is to demonstrate the ability of a biomarker test to identify a patient population in which antibacterial treatment provides no clear benefit. This is a multi-center, randomized, placebo-controlled, non-inferiority study of azithromycin treatment in adults vs. placebo with suspect lower respiratory tract infection and a procalcitonin level of <0.1 ng/mL. The overall goal is:
To determine whether a PCT level < 0.1 ng/mL identifies a subgroup of patients with lower respiratory tract infection (LRTI) who do not require antibiotic therapy versus placebo in patients with suspect LRTI and PCT levels of <0.1
|VENOUS||Prospective Evaluation of Clinical Outcomes of Cancer Patients with Vancomycin-Resistant ENterococcUS faecium (VRE) Bacteremia||Prospective Evaluation of Clinical Outcomes of Cancer Patients with Vancomycin-Resistant Enterococcus faecium (VRE) Bacteremia||This study is a multi-site observational study to prospectively evaluate the outcomes of patients with VRE BSIs treated with DAP and compare the outcomes stratifying by MIC. The study will obtain clinical information of cancer patients with VRE BSIs in an attempt to support the data-driven hypothesis that patients infected with DAP-S VRE isolates with a DAP MIC close to the breakpoint (3-4 μg/mL) are more likely to fail DAP therapy. Isolates will be collected to confirm their species and repeat the DAP MIC using Etest in a standardized and centralized manner. Isolates will remain available to perform further molecular testing in subsequent studies attempting to identify genetic signatures that may predict DAP failure.||4/14/2016||Enrollment Complete|